MS

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Retrieved on: 
星期四, 十一月 9, 2023
Survival, PNAS, IND, Stanford University, Patent, SOD1, KTTA, Clinical professor, Behavior, National academy, CNS, Natalizumab, Research, HIV disease progression rates, FN, Oregon Health & Science University, Disease, ALS, Multiple sclerosis, Integrin, Patient, Mayo Clinic, MS, SAN, Central nervous system, Pharmaceutical industry, Pasithea (Charites), Nature

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
  • This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
  • Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.

ROHM’s New Ultra-High-Speed Gate Driver IC: Maximizing the Performance of GaN Devices

Retrieved on: 
星期三, 十一月 8, 2023
Internet of things, ROHM, Department of Electrical Engineering and Information Technology of TU Darmstadt, Rohm, APEX, National Chiao Tung University, NCU, National Taipei University of Technology, BS, DC-DC, JJAP, AC-DC, Research, WLCSP, National Taipei University, Gallium nitride, Pulse, MS, University, Chang Gung University, Japanese Journal of Applied Physics, National Central University, Electricity, Miniaturization, Applied Physics Express, Silicon, Electric motor, Electronics, Lidar

This was facilitated through a deep understanding of GaN technology and the continuing pursuit of gate driver performance.

Key Points: 
  • This was facilitated through a deep understanding of GaN technology and the continuing pursuit of gate driver performance.
  • As these applications require the use of high-speed switching devices, in conjunction with the release of GaN devices, ROHM developed an ultra-high-speed gate driver IC that maximizes GaN performance.
  • As GaN devices are sensitive towards gate input overvoltage, ROHM has developed a unique method to suppress the gate voltage overshoots and has implemented it into this driver.
  • On the other hand, to demonstrate the performance of GaN devices, gate driver IC that enable high-speed switching while taking into account the low drive voltage of GaN HEMTs are essential.

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Retrieved on: 
星期三, 十一月 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ATRA, EDSS, CDI, Epstein–Barr virus, Biologics license application, PMS, Biomarker, Northwest Biotherapeutics, ASH, Partnership, MS, Disability, Cancer, Autoimmunity, EBV, Patient, BLA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).
  • The study did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.
  • In addition, fluid and imaging biomarkers did not provide further supportive evidence.
  • "We are surprised and deeply disappointed with the results of EMBOLD, particularly for the MS patient community which is in urgent need of new treatment options.

Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs R&D Partnership Agreement for Development of GLP1 Supplement for Pets

Retrieved on: 
星期三, 十一月 8, 2023
Faculty, NYSE, São Paulo, Federal University of Rio Grande do Sul, Obesity, Cat, Université de Montréal Faculty of Veterinary Medicine, Pet, Doctor of Philosophy, Rio, UNESP, APH, Veterinary medicine, MOU, Medical school, Faculty of Medicine, University of Colombo, University of São Paulo, UFRGS, Animal, University, Universidad, Overweight, Better Choice Parking, Pain management, GLP1, Dog, MS, Physiology, Medicine, Pharmacology, Anesthesia

TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.

Key Points: 
  • TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
  • The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals.
  • In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
  • We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector,” commented Mike Young, Chairman of the Board for Better Choice.

KATE FARMS APPOINTS PHYSICIAN AND REGISTERED DIETITIAN CHRISTINA J. VALENTINE TO CHIEF MEDICAL OFFICER POST

Retrieved on: 
星期三, 十一月 8, 2023
Texas Children's Hospital, University, Conditional sentence, Medical Affairs Bureau, Preterm birth, Dicarboxylic acid, Pregnancy, Health, DHA, Food, Heart, Nationwide, Behavior, Ball State University, PubMed, Baylor College of Medicine, Banner University Medical Center Tucson, Medicine, Ohio State University, Probability, RDN, Hospital, FAAP, Cognition, MS, Nursing, Dietary supplement, Neonatology, Science, Pediatrics

SANTA BARBARA, Calif., Nov. 8, 2023 /PRNewswire/ -- Chairman and Chief Executive Officer of Kate Farms Brett Matthews announced today the company has named Dr. Christina J. Valentine as its new Chief Medical Officer.

Key Points: 
  • SANTA BARBARA, Calif., Nov. 8, 2023 /PRNewswire/ -- Chairman and Chief Executive Officer of Kate Farms Brett Matthews announced today the company has named Dr. Christina J. Valentine as its new Chief Medical Officer.
  • Dr. Valentine is responsible for developing the vision and strategy for the Science and Clinical division, in alignment with Kate Farms' overall business strategy.
  • Dr. Valentine most recently served as Chief Medical Officer, Medical Affairs at Reckitt/Mead Johnson Nutrition.
  • "Our Chief Medical Officer is a critically important role at Kate Farms, requiring a combination of medical nutrition, clinical research and commercial expertise," said Matthews.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
星期二, 十一月 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions

Retrieved on: 
星期二, 十一月 7, 2023
Immune tolerance, Autoimmunity, Multiple sclerosis, LPX, Rheumatoid arthritis, TIM, Volunteering, Pharmacokinetics, Immune system, Safety, Therapy, Patient, MS, Lupus, Pharmaceutical industry, Vaccine

LPX-TI641 is a novel, and proprietary first-in-class orally bioavailable small molecule designed as a T cell immunoglobulin and mucin domain-containing protein (Tim) 3/4 receptor agonist.

Key Points: 
  • LPX-TI641 is a novel, and proprietary first-in-class orally bioavailable small molecule designed as a T cell immunoglobulin and mucin domain-containing protein (Tim) 3/4 receptor agonist.
  • LPX-TI641 restores the balance of regulatory immune cells (T- and B-regs) to autoreactive T-cells reestablishing immune tolerance.
  • It is being developed for the treatment of Multiple Sclerosis (MS) and potentially other autoimmune diseases such as rheumatoid arthritis and lupus.
  • The study is a randomized, double-blind, placebo-controlled study in healthy adult volunteers to evaluate the safety, tolerability, and pharmacokinetics of LPX-TI641 after single ascending oral doses.

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期二, 十一月 7, 2023
VISTA, Research, Insurance, Research and development, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, ESMO, CD28, Therapy, Society for Immunotherapy of Cancer, VSIG4, Active, Safety, Conference, Translation, MBA, R, Protein, Pharmacokinetics, SITC, Immunotherapy, Sensei, Neoplasm, CD39, Cytokine release syndrome, Annual general meeting, Kinetics, CET, Tumor microenvironment, Society, Cancer, European Society for Medical Oncology, Patient, Administration, MS, Toxicity, Pharmaceutical industry, Vaccine, Cryptocurrency, Antibody, Science, Survival

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Retrieved on: 
星期二, 十一月 7, 2023
ACT, Bioenergetics, Microsoft Access, Science, EAP, Survival, FDA, Research, NINDS, Food, Mortality, CNM, Gold, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SALT, Engineering, ALS, Clinical trial, Medicine, Risk, Biology, Physics, MOA, Bangladesh Technical Education Board, Consultant, Columbia University, Small, Multiple sclerosis, NIH, DSM-IV codes, EAPS, Chemistry, Patient, Death, MS, National Institute of Neurological Disorders and Stroke, Cryptocurrency, Pharmaceutical industry, Stroke

In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.

Key Points: 
  • In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.
  • Clene expects that its resources as of September 30, 2023, will be sufficient to fund its operations into the third quarter of 2024.
  • Research and development expenses were $6.0 million for the quarter ended September 30, 2023, compared to $6.4 million for the same period in 2022.
  • General and administrative expenses were $3.7 million for the quarter ended September 30, 2023, compared to $3.6 million for the same period in 2022.

Genzeon Launches HIP One, an Intelligence Platform Designed Specifically for Healthcare

Retrieved on: 
星期二, 十一月 7, 2023
Online Privacy, Technology, Security, Health Technology, Software, Practice Management, General Health, Health, Data Management, Artificial Intelligence, Intelligence, EVP, HIP, SVP, News, Organization, Generative, MBA, Multimedia, CDIO, Privacy, MS, Health care, Medical device, Nuance

Genzeon , a leading technology solutions provider, announced the launch of HIP One, a secure intelligence platform designed specifically for healthcare.

Key Points: 
  • Genzeon , a leading technology solutions provider, announced the launch of HIP One, a secure intelligence platform designed specifically for healthcare.
  • View the full release here: https://www.businesswire.com/news/home/20231107984941/en/
    HIP One Platform dashboard screen, featuring modules HIP Operations, HIP Clinical, and HIP Connect.
  • HIP One leverages the expertise of the Genzeon Healthcare team, including compliance and privacy, and is powered by generative artificial intelligence (GenAI).
  • To learn more about Genzeon’s HIP One platform and how to sign up for a free trial, please visit https://www.genzeon.com/healthcare/hip-one/ .